HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
NORCROSS, Ga., March 27, 2017 -- OmniMax Holdings, Inc. (formerly known as Euramax Holdings, Inc.) announced today that it will host an investor conference call regarding its fourth quarter and full year 2016 financial results at 2:00 PM Eastern Time on Wednesday, April 5, 2017. Existing bond holders, qualified institutional investors and securities analysts can obtain dial-in information upon registration at the OmniMax Investor Relations website at http://www.omnimax.com/investor-relations.
Contact Information OmniMax Holdings, Inc. Mary S. Cullin, 770-449-7066 Senior Vice President, Chief Financial Officer and Treasurer Email: [email protected]
